The Patent Finder

Alto Neuroscience, Inc.

21 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Amelioration of Neural Deficits Associated with Diabetes (US 10,322,115) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Amelioration of Certain Deficiencies Due to Stroke (US 10,413,534) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 2 fees due May 14, 2027
  • 1 fee due Sep 8, 2027
    The maintenance fee for Synthesis of a Neurostimulative Piperazine (US 9,278,933) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,673,916Methods of Treating Disorders Mediated by Histamine H3 Receptors Using Pyridazinone Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,207,168Pyridazinone Derivatives
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 8,586,588Aryl Pyridazinone Derivatives and Their Use as H3 Receptor Ligands
In force
 · High confidence
In forceHigh confidence
US 8,247,414Pyridizinone Derivatives and the Use Thereof as H3 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,524,713Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands
In force
 · High confidence
In forceHigh confidence
US 9,278,933Synthesis of a Neurostimulative Piperazine
In force
 · High confidence
In forceHigh confidence
US 9,481,649Synthesis of a neurostimulative piperazine
In force
 · USPTO record
In forceUSPTO record
US 9,572,807Protocols for Treatment of Major Depressive Disorder (MDD)
In force
 · High confidence
In forceHigh confidence
US 10,322,115Amelioration of Neural Deficits Associated with Diabetes
In force
 · High confidence
In forceHigh confidence
US 10,413,534Amelioration of Certain Deficiencies Due to Stroke
In force
 · High confidence
In forceHigh confidence
10 of 21 patents shown.
Pro members see all 21.
Pro members: see all 21 patents
Also on record, not counted in the 21: 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 9 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited